Life (Aug 2024)

Exploring the Th2 Response in Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Potential Modulator of the Renin-Angiotensin System (RAS) Pathway in Hypertension Development

  • Lucía Angélica Méndez-García,
  • Galileo Escobedo,
  • Itzel Baltazar-Pérez,
  • Nydia Angélica Ocampo-Aguilera,
  • José Alfonso Arreola-Miranda,
  • Miguel Angel Cid-Soto,
  • Ana Alfaro-Cruz,
  • Antonio González-Chávez,
  • Aquiles Ranferi Ocaña-Guzmán,
  • Helena Solleiro-Villavicencio

DOI
https://doi.org/10.3390/life14091080
Journal volume & issue
Vol. 14, no. 9
p. 1080

Abstract

Read online

Non-alcoholic fatty liver disease (NAFLD), now referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), is alarmingly increasing alongside the cases of obesity worldwide. MASLD is an underestimated metabolic abnormality closely linked with a higher risk of developing systemic arterial hypertension (SAH). However, the underlying mechanism of association between MASLD and SAH remains unknown. Inflammation may link these two entities by regulating the renin-angiotensin system (RAS). For this reason, in this study, we evaluated the hepatic expression of a cytokine profile and critical molecules in the RAS pathway in patients with morbid obesity and MASLD, both with SAH. We found a statistically significant correlation between ACE levels and the cytokines IL-4, IL-10, and IL-13 of Th2 response. Furthermore, according to a multiple linear regression analysis, the cytokines IL-4 and IL-13 were the best predictors of ACE levels. Moreover, we observed increased hepatic IL-13 expression in patients with morbid obesity, MASLD, and SAH compared to those without SAH. These results allow us to propose, for the first time, that the Th2 response, through regulating the RAS, could play a critical role in developing SAH in individuals with MASLD and obesity.

Keywords